SAB Biotherapeutics (SABS) Competitors

SAB Biotherapeutics (NASDAQ:SABS) and Agenus (NASDAQ:AGEN) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, community ranking, analyst recommendations, media sentiment, profitability, earnings, dividends and risk.

Do analysts prefer SABS or AGEN?

SAB Biotherapeutics presently has a consensus target price of $11.40, indicating a potential upside of 566.28%. Agenus has a consensus target price of $8.75, indicating a potential upside of 205.94%. Given SAB Biotherapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe SAB Biotherapeutics is more favorable than Agenus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SAB Biotherapeutics	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00
Agenus	0 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.17

Which has higher valuation and earnings, SABS or AGEN?

SAB Biotherapeutics has higher earnings, but lower revenue than Agenus. SAB Biotherapeutics is trading at a lower price-to-earnings ratio than Agenus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SAB Biotherapeutics	$2.24M	7.10	-$42.19M	-$3.68	-0.46
Agenus	$103.46M	0.70	-$245.76M	-$10.68	-0.27

Which has more risk & volatility, SABS or AGEN?

SAB Biotherapeutics has a beta of 0.52, indicating that its stock price is 48% less volatile than the S&P 500. Comparatively, Agenus has a beta of 1.58, indicating that its stock price is 58% more volatile than the S&P 500.

Does the media favor SABS or AGEN?

In the previous week, Agenus had 13 more articles in the media than SAB Biotherapeutics. MarketBeat recorded 16 mentions for Agenus and 3 mentions for SAB Biotherapeutics. SAB Biotherapeutics' average media sentiment score of 0.96 beat Agenus' score of 0.19 indicating that SAB Biotherapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
SAB Biotherapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Agenus	2 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	4 Very Negative mention(s)	Neutral

Do institutionals & insiders hold more shares of SABS or AGEN?

7.8% of SAB Biotherapeutics shares are owned by institutional investors. Comparatively, 61.5% of Agenus shares are owned by institutional investors. 26.5% of SAB Biotherapeutics shares are owned by insiders. Comparatively, 4.6% of Agenus shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Does the MarketBeat Community favor SABS or AGEN?

Agenus received 437 more outperform votes than SAB Biotherapeutics when rated by MarketBeat users. However, 83.78% of users gave SAB Biotherapeutics an outperform vote while only 68.72% of users gave Agenus an outperform vote.

Company	Underperform	Outperform
SAB Biotherapeutics	Outperform Votes 31 83.78%	Underperform Votes 6 16.22%
Agenus	Outperform Votes 468 68.72%	Underperform Votes 213 31.28%

Is SABS or AGEN more profitable?

Agenus has a net margin of -145.89% compared to SAB Biotherapeutics' net margin of -1,450.14%. Agenus' return on equity of 0.00% beat SAB Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SAB Biotherapeutics	-1,450.14%	-94.37%	-67.26%
Agenus	-145.89%	N/A	-85.68%

Summary

SAB Biotherapeutics beats Agenus on 10 of the 18 factors compared between the two stocks.